Researchers from Tokyo Metropolitan University have created a new way of telling "aged" human cells apart from younger ones using electric fields. While key markers have been found for these "senescent" cells, current methods require biochemical "labels" which are difficult to apply and affect the cells themselves, making them difficult to study. The new method is label-free and less damaging. The team aims to diversify the method, extending it to other cell types.

Aging starts at the cellular level. As we get older, aged or "senescent" cells accumulate in our body. Not only have these cells lost much of their original function, but they continue to emit compounds which trigger inflammation. There is a growing body of evidence for how they play a part in aging-related conditions like arterial hardening, Alzheimer's disease, and type 2 diabetes.

To understand and treat such ailments, scientists need to come to grips with how senescent cells affect our physiology. Naturally, this starts with identifying which of our cells are senescent, and which are not. Unfortunately, existing methods rely on selective "labeling," e.g. the attachment of a fluorescent molecule to specific compounds known to be present in aged cells. Not only is this time-consuming and complex, but the process itself can change the properties of the very thing scientists want to study.

To get around this issue, a team led by Assistant Professor Ippei Yagi from Tokyo Metropolitan University has come up with an entirely different approach to identifying senescent cells. Instead of chemical labels, they put cells under an alternating electric field. This causes a slight rearrangement of charge, where one end of the cell is more positively charged than the other. When the electric field is not uniform over space, the cell migrates; in the case of an alternating field, the cell wanders backwards and forwards between the electrodes. As the frequency of the field is changed, the motion of the cell changes significantly at a value known as the cutoff frequency. The method, known as frequency-modulated dielectrophoresis (FM-DEP), aims to characterize cell type by measuring this value.

The team focused their efforts on human dermal fibroblasts, an important part of connective tissue in the skin. When they tested senescent cells against younger ones, they found that there was a marked difference in their cutoff frequencies. These changes come about from changes in the fatty (lipid) molecules which make up the membrane of the cells. Importantly, FM-DEP is rapid, easy to apply, and label-free.

The new method is not only a convenient tool for research into aging, but may see application to regenerative medicine, and drug screening. The team hope to apply FM-DEP to other cell types as well, as a versatile new approach to cell identification.

This work was supported by JSPS KAKENHI Grant Numbers JP23K28453 and JP23KK0260.

Read more …Zapping aging cells: The fast, label-free test that could transform research

In a follow up investigation into the multibillion dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in key platelet studies used in its FDA approval.

For more than a decade, ticagrelor (Brilinta in the US and Brilique in Europe) has been recommended for patients with acute coronary syndrome -- a range of conditions related to sudden reduced blood flow to the heart.

Last December, an investigation by The BMJ found serious data integrity problems in the landmark clinical trial (PLATO) that was used to gain worldwide approval for ticagrelor, calling into question the drug's advantage over cheaper rivals.

Now, as generic versions of the drug prepare to launch this year, The BMJ has expanded its investigation, looking at two key platelet studies that AstraZeneca claimed explained ticagrelor's ability to treat acute coronary syndrome successfully.

It finds that the "primary endpoint" results (the trial's key measurement) for both clinical trials were inaccurately reported in the leading cardiology journal Circulation, and reveals that more than 60 of 282 readings from platelet machines used in the trials were not present in US Food and Drug Administration (FDA) datasets.

What's more, one active trial investigator never became a study author, while one author told The BMJ he was not involved in the trial, and most investigators, including the principal investigator, were unreachable or declined to be interviewed.

Victor Serebruany, an adjunct faculty member at Johns Hopkins University and ticagrelor's most renowned critic, told The BMJ that "there are episodes of skyrocketing rebound and profound platelet inhibition after ticagrelor making patients prone to thrombosis or bleeding. If doctors had known what happened in these trials, they would never have started using ticagrelor."

Circulation and AstraZeneca did not respond to a request for comment.

Serebruany added: "It's been obvious for years that there is something wrong with the data. That the FDA's leadership could look past all these problems -- on top of the many problems their own reviewers identified and are now being discovered by The BMJ -- is unconscionable. We all need to know how and why that happened."

Read more …FDA under fire: Data discrepancies uncovered in AstraZeneca approval trials

More Articles …